Orlando, FL -- (SBWIRE) -- 08/23/2013 -- Hot Stock Profits provides investors and traders with valuable trading tools and content as well as micro-cap stock alerts via eMail and text messages. To Join Our Text Message Alerts Service Just Text The Word Stocks To 555888 From Your Cell Phone. Our Focus Today Is On Dominion Resources, Inc. (NYSE:D), Merrimack Pharmaceuticals Inc (NASDAQ:MACK).
Dominion Resources, Inc. (NYSE:D) shares gained 1.84% to $58.82 in the morning hour. The board of directors of Dominion has declared a quarterly dividend of 56.25 cents per share of common stock. Dividends are payable on Sept. 20, 2013, to shareholders of record at the close of business Sept. 6, 2013. This is the 342nd consecutive dividend that Dominion or its predecessor company has paid holders of common stock. The company's last quarterly dividend was declared May 3, 2013.
Should Investors Rush To Buy D After The Solid Rally? Get Special Report Here
Additionally, the company on August 6 said its second-quarter profit fell 22% as the company was hurt by charges and lower-than-expected revenue. The company reported a profit of $202 million, or 35 cents a share, down from $258 million, or 45 cents a share, a year earlier. On an operating basis, which excludes items including a loss from discontinued operations at Brayton Point and Kincaid power plants and a write-down of natural-gas infrastructure assets, earnings rose to 62 cents a share from 59 cents. The company had targeted a profit of 60 cents to 70 cents a share.
Merrimack Pharmaceuticals Inc (NASDAQ:MACK) shares declined 1.88% to $3.39. The company on August 22 announced that the British Journal of Cancer has published the paper "A Multinational Phase 2 Study of Nanoliposomal Irinotecan Sucrosofate (PEP02, MM-398) for Patients with Gemcitabine-Refractory Metastatic Pancreatic Cancer" in its latest issue (Volume 109, Issue 4). The Phase 2 study evaluated MM-398 (liposomal irinotecan sucrosulfate) monotherapy in patients with metastatic pancreatic cancer previously treated with gemcitabine-based therapy.
Can Traders Buy MACK After The Solid Rally? Get Free Trend Analysis Here
Additionally, the company on August 13 announced that the U.S. Food and Drug Administration'sOffice of Orphan Products Development has granted two separate orphan drug designations for its bispecific antibody, MM-111, for the treatment of esophageal cancer and for the treatment of gastric as well as gastroesophageal junction (GEJ) cancers.
Join Our Mobile SMS Alerts By Texting Stocks To 555888
HotStockProfits.com continuously monitors and scans the markets for day trading and swing trading signals on NASDAQ, NYSE, AMEX, OTCBB and Pink Sheet companies for its free e-newsletter subscribers.
Disclosure: HotStockProfits.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit HotStockProfits.com website, for complete risks and disclosures.
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)